靶向整合素α2作为胶质母细胞瘤放化疗增敏的潜在策略
该研究在体外和体内胶质母细胞瘤(GBM)模型中探讨黏附蛋白整合素α2的作用,发现其在GBM中高表达,敲低后可增强替莫唑胺(TMZ)和放疗的敏感性,减少侵袭和黏附,抑制增殖且不影响DNA损伤修复,并延长原位移植瘤小鼠生存。作者认为整合素α2可能是克服GBM放化疗耐药的有前景靶点,值得评估其抑制剂辅助标准放化疗的效率与安全性。
要点
- 整合素α2在GBM中较正常脑组织高表达,其缺失可导致放化疗增敏。
- 整合素α2敲低减少TMZ联合照射GBM细胞的侵袭和黏附,抑制增殖但不影响DNA损伤修复。
- 整合素α2缺失抑制原位GBM移植瘤生长并延长小鼠生存。
核心结论
- 数据提示整合素α2可能是克服GBM放化疗耐药的有前景靶点,值得评估整合素α2抑制剂辅助标准放化疗的效率与安全性。
研究设计与样本
- 研究使用多种原代/干细胞样及已建立的GBM细胞模型进行体外和体内实验。
- 采用高通量激酶组谱分析、蛋白质印迹、免疫荧光染色、报告基因和活性实验鉴定调控机制。
主要发现
- 整合素α2在GBM中较正常脑组织高表达,其缺失导致放化疗增敏。
- 在TMZ照射的GBM细胞模型中,侵袭和黏附显著降低。
- 整合素α2敲低抑制GBM细胞增殖,但不影响DNA损伤修复。
- 机制上,整合素α2影响激活转录因子1(ATF1)活性并调节细胞外信号调节激酶1(ERK1)的表达。
- 整合素α2缺失抑制原位GBM移植瘤生长,延长小鼠生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is a fast-growing primary brain tumor characterized by high invasiveness and resistance. This results in poor patient survival. Resistance is caused by many factors, including cell-extracellular matrix (ECM) interactions. Here, we addressed the role of adhesion protein integrin α2, which we identified in a high-throughput screen for novel potential targets in GBM cells treated with standard therapy consisting of temozolomide (TMZ) and radiation. METHODS: In our study, we used a range of primary/stem-like and established GBM cell models in vitro and in vivo. To identify regulatory mechanisms, we employed high-throughput kinome profiling, Western blotting, immunofluorescence staining, reporter, and activity assays. RESULTS: Our data showed that integrin α2 is overexpressed in GBM compared to normal brain and, that its deletion causes radiochemosensitization. Similarly, invasion and adhesion were significantly reduced in TMZ-irradiated GBM cell models. Furthermore, we found that integrin α2-knockdown impairs the proliferation of GBM cells without affecting DNA damage repair. At the mechanistic level, we found that integrin α2 affects the activity of activating transcription factor 1 (ATF1) and modulates the expression of extracellular signal-regulated kinase 1 (ERK1) regulated by extracellular signals. Finally, we demonstrated that integrin α2-deficiency inhibits tumor growth and thereby prolongs the survival of mice with orthotopically growing GBM xenografts. CONCLUSIONS: Taken together our data suggest that integrin α2 may be a promising target to overcome GBM resistance to radio- and chemotherapy. Thus, it would be worth evaluating how efficient and safe the adjuvant use of integrin α2 inhibitors is to standard radio(chemo)therapy in GBM.
引用
- Korovina I, Vehlow A, Temme A, et al. Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma. Neuro Oncol. 2023. PMID: 36219689. doi:10.1093/neuonc/noac237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。